Salha Sassi, D Ahirwar, T Wilkie, L Elgaddafi and Ramesh K Ganju
Ohio State University, USA
Posters & Accepted Abstracts: J Cancer Sci Ther
Small cell lung cancer (SCLC) represents 20% of lung cancers and is characterized by early dissemination, development of
chemo resistance and a poor prognosis. Small cell lung cancer (SCLC) is a highly aggressive malignancy with a limited
spectrum of therapeutic options. Therefore, identifying early biomarkers and targets may lead to the development of innovative
therapies that will improve the survival of SCLC patients. Slit2, a secreted glycoprotein, has been shown to be suppressed
in a number of cancers. Slit2 has recently emerged as an important tumor suppressor gene and acts through Roundabout
Homolog1 (Robo1) receptor. Slit2/Robo1 signaling has been reported to inhibit the migration of a variety of cancer cells
including non-small cell lung cancer (NSCLC). The chemokine receptor CXCR4 and its cognate chemotactic ligand CXCL12
play an important role in cell migration, cancer growth, angiogenesis, and metastasis. However, the molecular mechanism by
which the Slit/Robo complex inhibits the migration of small cell lung cancer is not well defined.
Aims: Determine Slit2 and Robo1 expression in a wide range of pulmonary neuroendocrine carcinomas (NEC), including
SCLC and in human SCLC patient samples 2. Analyze the role of Slit2 in tumor growth and metastasis in vivo using a Small
cell lung cancer mouse model 3. Investigate the role of Slit2/Robo1 signaling pathway modulates the CXCL12/CXCR4-induced
chemo taxis and metastasis in Small cell lung cancer.
Salha Sassi is persuing his PhD in Department of Pathology , Ohio State University. His research interest in Cancer biology and cell signaling mechanisms.
E-mail: sassi.4@osu.edu
Cancer Science & Therapy received 3968 citations as per Google Scholar report